PranaX Corporation Secures $17M in Series A Funding
Houston has a way of hiding serious science in plain sight. Tucked inside the Levit Green life sciences district, steps from the Texas Medical Center, PranaX Corporation has been quietly building something that does not shout, does not posture, and does not apologize. Founded in November 2022 by Steven J. Greco, PhD, PranaX was designed around a simple premise with a long shadow: if cells already know how to heal, maybe the smartest move is to listen to what they are saying.
That conversation happens through exosomes, microscopic messengers measuring 30 to 150 nanometers, carrying instructions that tell tissues how to repair, regulate, and recover. PranaX did not source this idea from a trend deck. The company secured an exclusive license in March 2025 from The University of Texas MD Anderson Cancer Center, built on work led by Valerie S. Kalluri, MD PhD MBA and Raghu Kalluri, MD PhD, whose research helped power the first FDA-approved clinical trial of mesenchymal stem cell-derived exosomes in humans.
This matters because most wellness narratives float on vibes. PranaX operates on validation. In October 2025, the licensed manufacturing platform was published in Nature Communications, documenting human safety data with negligible toxicity and no serious adverse events. That is not marketing. That is peer-reviewed oxygen in a market crowded with smoke.
PranaX closed an oversubscribed $17 million Series A round, bringing total capital raised to $27 million. The round was backed by family offices, trusts, and individual investors who understand that biology rewards patience and precision. The capital lands as PranaX scales inside its 7,400 square foot FDA-registered, cGMP-compliant facility, complete with an ISO 7 cleanroom built specifically for exosome production.
Leadership reflects the same discipline. Steven J. Greco, PhD, Founder and Chief Operating Officer, brings decades of stem cell biology focused on aging and neurodegeneration. Phillip Maderia, Chief Executive Officer, joined in February 2025 after leading large-scale GMP exosome manufacturing at Lonza, including 500-liter production systems that separate theory from throughput.
The product stack stays close to the science. ExoWELL is a physician-directed, GMP-grade exosome supplement grounded in clinical manufacturing standards. ExoSTORE offers personalized exosome banking, capturing biological signals today for potential use tomorrow. Both live inside a company name that fits. PranaX sounds like breath because that is what this feels like. A measured inhale before regenerative biologics stop being speculative conversation and start becoming infrastructure.